An allogeneic tumor cell vaccine should display a natural immunogenicity that allows the stimulation of tumor-reactive effector cells in patients. Furthermore, the vaccine should express antigens that are shared by many tumors to which patients are not tolerant. A variety of tumor peptides should be presented by different HLA-molecules due to limited MHC matching with recipients and last but not least, the vaccine should have a strong growth potential in vitro to allow adequate amounts of vaccine to be generated for long-term usage. The primary treatment for RCC is radical nephrectomy, which may be curative in the absence of metastases. However, at the time of diagnosis 50-60% of patients with RCC have distant metastases. The 5-year survival rate of these
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The primary treatment for RCC is radical nephrectomy, which may be curative in the absence of metastases. However, at the time of diagnosis 50-60% of patients with RCC have distant metastases. The 5-year survival rate of these Correspondence: Dr H Pohla, Laboratory for Tumor Immunology, Department of Urology, Ludwig-Maximilians-University Munich, Marchioninistr 23, D-81377 Munich, Germany patients is less than 10%. No effective treatment strategy exists because RCC is relatively radio-, hormone-and chemoresistant. New treatment modalities are urgently needed and immunotherapy promises some hope. RCC, like melanoma, is classified as immunogenic, based on occurrence of spontaneous remission and response to cytokine therapy. Despite reported remissions under combined immuno/chemotherapy, substantial clinical benefit has not been shown and high toxicity often limits broad application. Furthermore, due to an early tumor dissemination most patients already bear occult tumor cells, despite the removal of the primary tumor and the absence of evidence for metastases. Patients with minimal residual disease could benefit the most from immunological approaches. Several clinical studies have been initiated using genetically-modified autologous tumor vaccines, sometimes admixed with fibroblasts 1 or fused with allogeneic antigen-presenting cells. 2 Severe toxicity was not seen but clinical success was also rare. This, however, need not indicate that antitumor immune responses were not induced, since the only immunological parameter usually analyzed after vaccination was a delayed type hypersensitivity (DTH) skin reaction. Reliable evaluation of the immunological effects induced by vaccination is critical for judging experimental therapies, particularly when patients with advanced disease are treated in whom clinical benefit is difficult to achieve. Two allogeneic vaccination protocols using genetically modified RCC cell lines (RCC-26/IL-2/B7.1; RCC-26/IL-7/B7.1) with improved immunogenicity are to be initiated shortly for the treatment of patients matched for HLA-A* 0201. 3 We have developed a simple strategy for patient selection based on a nested polymerase chain reaction (PCR) with sequence specific primers for the HLA-A*0201 allele. 4 Since only partial matching is feasible with this approach, the allogeneic tumor vaccine will induce alloreactive T cells, similar to those induced in transplantation between unmatched individuals. The present report demonstrates the feasibility of using an allogeneic tumor vaccine and describes approaches for monitoring the development of immune responses.
Materials and methods

Establishment of TIL, RCC, NKC, LCL and in vitro primed CTL
Tumor infiltrating lymphocytes (TIL) and RCC were isolated from primary tumor material as described previously. 3, 5 The genetically modified RCC cell lines were established by T Blankenstein (MDC, Berlin, Germany). A normal kidney cell line (NKC-26) was established and immortalized by transfection with a retrovirus carrying the SV40 large T antigen (T Blankenstein). An autologous lymphoblastoid cell line (LCL-26) was established by EBV immortalization. Mixed lymphocyte tumor cell cultures (MLTC) were established using PBMC of HLA-A*0201-matched and unmatched patients and healthy control donors. Responder cells were stimulated with irradiated (100 Gy) RCC-26 in RPMI 1640 medium supplemented with 2 mm l-glutamine, 1 mm sodium pyruvate, 15% heatinactivated pooled human serum and penicillin/ streptomycin (100 U/ml). At least 4 h later 20 U/ml rIL-2 (Proleukin; Chiron, Rathingen, Germany) and 5 U/ml rIL-4 (kindly provided by EP Rieber, Institute of Immunology, Technical University Dresden, Germany) were added to the cultures.
RT-PCR-based TCR tracking
The methods used for RNA preparation, cDNA synthesis, TCR-specific PCR amplification and sequence analysis of the third complementarity-determining region (CDR3) are described in detail elsewhere. 6 
Cytotoxicity assays
Cell-mediated lysis was quantitated using a standard 4 h 51 chromium-release assay as described. 3 As an alternative, a triple-target lanthanide assay was developed. The labeling procedure of target cells in this assay is based on use of a stable lanthanide/DTPA (Titriplex V) chelate, which as a hydrophilic compound cannot penetrate cell membranes. Therefore, cells were treated with 500 mg/ml dextran sulphate in HEPES buffer (pH 7.4) containing lanthanide and DTPA in a ratio of 1:5 (RCC-26: 10 mm samarium, 50 mm DTPA; LCL-26: 100 m europium, 500 m DTPA; K562: 500 m terbium, 2.5 mm DTPA). Following 15 min incubation at 20°C, regeneration of the cell membranes was supported by washing the cells in repairing buffer containing 2 mm CaCl 2 and 10 mm glucose in HEPES and four washing steps in culture medium (RPMI 1640, 10% FCS).
Triplicates of each target cell (3000 cells of each type) were added to 100 l effector cells at different E:T ratios in round-bottom microtiter plates and incubated for 3 h at 37°C, 6.5% CO 2 . Twenty microliters of the released lanthanide/chelates were further incubated for 5 min in 180 l Delfia enhancement solution (Wallac, Turku, Finland) for the measurement of the Sm 3ϩ and Eu 3ϩ fluorescence. Fifteen minutes later, 20 l terbium enhancement solution was added for measuring the Tb 3ϩ fluorescence. Spontaneous release was determined by incubating the target cells alone and maximum release by incubating in 0.5% Titron X-100. For background evaluation, 100 l supernatant of the labeled target cell dilution were incubated in medium. These counts are subtracted from spontaneous and maximum release values. The percentage lysis for both assays was calculated using the formula: % lysis ϭ (experimental release Ϫ spontaneous release/maximum release Ϫ spontaneous release) ϫ 100.
ELISPOT assay
Nitrocellulose-bottomed microtiter plates (MultiScreen MAHA S4510, Millipore, Bedford, MA, USA) were coated overnight at 4°C with 100 l monoclonal mouse antihuman IFN␥ antibody per well (clone 1-D1K, Mabtech AB, Nacka, Sweden) at 15 mg/ml in 0.1 m NaHCO 3 /Na 2 CO 3 , pH 9.5. Wells were washed three times in PBS and then incubated with 50 l RPMI 1640 ϩ 10% human AB serum per well for 2 h at 37°C for blocking unspecific binding. The responder lymphocytes were plated first, titrated in triplicate with a starting concentration of 1.5 ϫ 10 5 cells in 100 l/well (or 5 ϫ 10 3 TIL-26); the stimulators were then carefully added (usually 3-5 ϫ 10 3 cells in 100 l/well). For background evaluation stimulators or responders alone were used. The assay medium was RPMI 1640 supplemented with 2 mm l-glutamine, 1 mm sodium pyruvate, 10% heat-inactivated pooled human serum or AB serum, penicillin/streptomycin (100 U/ml) and 20 U/ml rIL-2. After incubation for at least 18 h at 37°C in 6.5% CO 2 , the plates were washed thoroughly five times in PBS/0.05% Tween20 and then incubated with 100 l biotinylated mouse anti-human IFN␥ antibody (clone 7-B6-1, Mabtech) at 2 mg/ml in PBS/1% FCS for 2 h at 37°C. Following washing (4 ϫ in PBS/Tween20), 100 l ExtrAvidin peroxidase conjugate (Sigma, Munich, Germany), diluted 1:1000 in PBS were added and the plate incubated for 1 h at room temperature. After the next washing step (2 ϫ in PBS/Tween, 3 ϫ in PBS) 100 l diamino benzidine (Sigma FAST DAB: two tablets DAB and two tablets urea-H 2 O 2 per 10 ml deionized H 2 O) as peroxidase substrate were added. Brown spots appeared within 3-5 min. The reaction was stopped by rinsing the plate under tap water. After drying, the spots were evaluated under a stereomicroscope and automatic counting was made using computer-assisted video image analysis system (KS ELISPOT, Carl Zeiss Jena GmbH, Munich, Germany).
Results
RCC-26 fulfills the criteria of a good allogeneic vaccine
Extensive cellular and molecular analyses of CTL responses directed against RCC has been assessed using autologous and allogeneic TIL. 5, 6 The antigenic epitope recognized by TIL-26 on RCC-26 cells was not functionally detected on normal kidney cells (NKC-26), indicating that the HLA-A2-restricted ligand seen by these CTL is tumor-associated. Cytotoxic effectors present in TIL populations of other A*0201-matched RCC patients were also found to recognize their target epitopes on RCC-26 tumor cells. The recognition of RCC-26 could be blocked with anti-HLA-A2 and anti-HLA-A, -B, -C specific antibodies, demonstrating an MHC-restricted specificity for these TIL. Furthermore, the analysis of a panel of RCC tumor lines revealed that different TIL showed different patterns of recognition, indicating that they recognized distinct HLA-A2-restricted peptides. The RCC-26 vaccine could be used to restimulate allogeneic TIL in vitro, thus indicating that RCC-26 displays several ligands common to other RCC and, therefore, has the potential to prime de novo or to reactivate memory CTL in patients following vaccination that should be able to recognize epitopes displayed by residual tumor cells.
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PCR-based tracking of tumor-specific TCR sequences
Several MLTC using PBL of HLA-A*0201-matched and unmatched RCC patients and normal healthy donors were used to evaluate the stimulatory capacity of RCC-26 and to determine whether PCR-based TCR tracking is suitable 6 supporting the hypothesis that these TIL recognized a common epitope that led to their antigen-driven selection in vivo. Analysis of PBL-26 revealed that T cells with such TCR were continually circulating in the periphery over a period of 4 years.
The lanthanide-release assay
Normally the frequency of CTL specific for a single peptide/MHC complex in naive circulating PBL populations appears to be less than one in a million lymphocytes. 7 Therefore, techniques designed to measure changes in such cells following vaccination must be highly sensitive. The most common approach used to estimate the frequency of tumor-specific CTL precursors is a limiting dilution killer assay using the classical 51 Cr-release method. To distinguish tumor-specific, allospecific and non-MHCrestricted effector cell populations, the microcultures must be divided and tested against different target cells (eg RCC-26, LCL-26 or NKC-26 and K562). Using the non-radio- Figure 2 Cytolytic activity of TIL-26: comparison of (a) 51 chromium and (b) lanthanide-release assays. The assays were performed using triplicates of varying effector to target (E:T) cell ratios with a target cell concentration of 3 ϫ 10 3 . Data are presented as percentage of specific lysis. In the lanthanide assay the following labels were used: samarium (RCC-26), terbium (K562) and europium (LCL-26).
active lanthanide-release assay, 8 three target cells, each labeled with a different lanthanide (europium, samarium and terbium), can be simultaneously evaluated in the same well without the need to split the cultures, as shown in Figure  1 . Due to the different emission spectra and decay times of the long-lived fluorescent lanthanide ions, as compared to the short-lived background fluorescence in the culture medium, the specific release from the three target cells is measured using a time-resolved fluorometer (Wallac 1420 Victor). As shown in Figure 2 both cytotoxic assays are comparably sensitive for detecting the lytic activity of TIL-26.
As a routine method, lanthanide assays have the following advantages: the measurement time is only 1 s/well; the release of the label is often higher when compared to 51 Cr, allowing a shorter incubation period; the use of multiple labels is possible and the target cells can be labeled in advance and cryopreserved for long-term storage. However, a major disadvantage of both cytotoxic assays is that stimulation of the effector PBL in bulk cultures with vaccine cells (2-3 consecutive times before setting up the limiting dilution culture) is required to expand specific CTL to amounts that are detectable in these assays. Furthermore, cold-target competition assays must be done to verify the tumor-specific reactivity. Limiting dilution assays are not always sensitive enough to detect small changes; they are difficult to perform because the culture conditions must follow single hit kinetics.
The ELISPOT assay: sensitive quantification on single cell level
To date no clinically relevant RCC-associated tumor antigen is known, therefore we have only the possibility to use the allogeneic tumor cell line RCC-26 as a stimulator cell in the ELISPOT assay or dendritic cells pulsed with tumor cell lysate. Figure 3 demonstrates the feasibility of using adherent growing allogeneic cells like RCC-26 and NKC-26 as stimulator cells. Furthermore, blocking experiments with HLA class I antibodies can be also done quite easily to reveal MHC-restricted immune responses. For IFN␥-ELISPOT assays, an enrichment of the effector T cells is not necessary because the majority of peripheral blood cells are T cells. To evaluate the frequencies of tumor-specific CD8 ϩ or CD4 ϩ T cell populations separately, enrichment procedures using magnetic beads are possible. The amount of blood available in clinical settings is also sufficient for additional IL-4 and IL-10 ELISPOTs (data not shown here).
Discussion
We have applied autologous TIL-26/RCC-26 as a model system for evaluating a genetically modified RCC line as an allogeneic vaccine for the treatment of patients with advanced RCC. RCC-26 shows stable, high expression of MHC class I molecules, high levels of CD54 and CD58, and also expresses CD40 but not the costimulatory molecules CD80 and CD86. To develop a vaccine with optimized stimulatory capacity genetically modified RCC-26 cells were generated by retroviral transduction to express the CD80 (B7.1) together with either IL-2 or IL-7. Animal models have demonstrated that genetically modified vaccine cell lines directly induce T lymphocytes in vivo, but also following T cell-mediated lysis of the vaccine, uptake and processing of tumor-associated antigens by dendritic cells can lead to activation of T cells (so called 'crosspriming'). 9 Functional cytotoxicity assays as well as molecular TCR repertoire analyses of the effector cells derived from MLTC using unmodified and modified RCC-26 cell lines revealed that: (1) RCC-26 has a natural capacity for antigen presentation; (2) CD80 seems not be required for reactivation of memory effector cells but is required for de novo priming of effector T cells from naive populations; (3) tumorreactive T cells emerge from allogeneic MLTC; and (4) MHC-restricted T cells with specific TCR can be recruited to the immune response. Such CTL responses have all the characteristics of an antigen-driven secondary immune response: highly restricted V-J and V-D-J gene segment usage, highly restricted CDR3 loop lengths and selection for particular amino acids in the N-region. 10 The ELISPOT assay as an earlier read-out technique offers many advantages in a clinical setting. First, it does not require any in vitro proliferation and can detect tumorspecific T cell responses among peripheral blood cells. This eliminates the in vitro selection of cells that accompanies long-term cultures. Second, it seems to be at least 20-100 times more sensitive than the 51 Cr-release and therefore requires fewer effector cells. In general, each spot reflects a single cytokine-producing cell, which allows not only the enumeration of rare antigen-specific T cells but also quantifies the frequency of tumor-specific T cells before, during and after immunotherapy.
The possibility to track tumor-antigen specific TCR by PCR and direct amplicon sequencing on the one hand and measurement of specific IFN␥-or IL-4-producing effector cells by the ELISPOT on the other, means that sensitive monitoring of allogeneic cellular vaccine trials is feasible even though tumor-associated antigens remain undefined. While clinical benefit for these patients may be difficult to achieve because of the advanced stage of disease, monitoring data should demonstrate whether induction of antitumor Bone Marrow Transplantation responses has been achieved in these patients, opening the possibility of evaluating allogeneic vaccination in the situation of minimal residual disease.
